FGFR2 and gastric adenocarcinoma: Bemarituzumab, an afucosylated mAb against FGFR2b, induced confirmed objective responses in 5 (18%) out of 28 patients with CHT-refractory gastric adenocarcinoma characterized by FGFR2 amplification and elevated FGFR2b overexpression [199].